Borderline Personality Disorder
Conditions
Keywords
Psychiatry, Suicidal Behavior, Borderline Personality Disorder, Follow-Up Study
Brief summary
Borderline Personality Disorder (BPD) is a common psychiatric disorder occurring in 2 to 6% of the population. 70% of patients with BPD do at least one Suicide Attempt (SA) in their lives. It makes BPD the most related to SA condition. Negative interpersonal events are among the main stressor inducing a SA. Patients with BPD are characterized by emotional dysregulation, impulsivity (repeated parasuicidal and suicidal behaviors), and instability in interpersonal relationships. The feeling of shame related to this psychiatric disorder could be one of the causes of the high SA rate. In this study, patients with BPD will be follow-up during 5 years. The main objective is to study the propensity to feel shame as a predictor of SA. This include: * Study of shame propensity as a predictive factor of suicidal behavior - Identify homogeneous subgroups of patients with BPD based on SA, and overall functioning. * Identify biological markers predicting SA * Identify predictive and protective treatments (pharmacological and psychotherapeutic) for SA
Detailed description
This is a 5 years follow-up prospective study recruiting 688 patients. Schedule of the study : Inclusion period : 3 years Duration of follow-up of each patient : 5 years Estimated duration of the study : 8.5 years As part of the research, patients will be summoned annually for 5 years. The first visit (at baseline) is included in the usual care The follow-up visits are specifics to the research During the visits patients will complete self questionary and clinical interview. The organization of visits is as follows: * an inclusion visit lasting around 2 hours (clinical evaluation and then self-questionnaires) * a visit to 1 year, 2 years, 3 years, 4 years and 5 years (+/- 1 month) lasting approximately 1 hour 30 (clinical evaluation and passing of self-questionnaires) Genetic samples will be taken during the initial visit as well as during the visit to 5 years. They consist of: * A genetic collection consisting of a DNA library (3 Ethylene Diamine Triacetic Acid (EDTA) tubes of 6ml - 18 ml). * An off-genetics collection consisting of serum and plasma samples, (1 6 ml EDTA tube, 1 4 ml heparinized tube, 2 dry tubes of 5 ml each and 2 citrated tubes of 2.7 ml each - 25 , 4 ml).
Interventions
OTHERClinical and biological assessments - a 5 Years follow-up
During each visit, a clinical evaluation will be carried out, as well as the filling of hetero-questionnaires and self-questionnaires. Two biological collections will be made: one during the inclusion visit, and the other during the last visit, 5 years after inclusion.
Sponsors
INSERM 1061, Neuropsychiatry: epidemiological and clinical research, Montpellier
University Hospital, Montpellier
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Intervention model description
During each visit, a clinical evaluation will be carried out, as well as the filling of hetero-questionnaires and self-questionnaires. Two biological collections will be made: one during the inclusion visit, and the other during the last visit, 5 years after inclusion. First visit (Baseline) only: Sociodemographic data, Clinical evaluation, family history At Baseline and 5 years after baseline only: * Blood sample * BPD diagnosis (using the Structured Clinical Interview for Diagnostic and Statistical Manual (DSM) Disorders (SCID II))
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* To be over 18 * Clinical diagnosis of BPD using the SCID II (Structured Clinical Interview for DSM-IV-Text Reviewed Axis II Personality Disorders) * Having signed the informed consent * Able to understand the nature, the purpose and the methodology of the study * Able to understand and perform the clinical evaluations
Exclusion criteria
* Deprived of liberty (by judicial or administrative decision) * Protected by law (guardianship) * Exclusion period in relation to another protocol * Not affiliated to a social security scheme
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Level of shame propensity | At enrollment | Evaluation of the level of shame propensity will be measured using the Test of Self Conscious Affect (TOSCA) |
| Number of SA compared to the clinical data obtained in baseline | At enrollment | The number of SA will be collected using Columbia Suicide Severity Rating Scale (C-SSRS) and compared to the clinical data obtained in baseline |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Parasuicidal Behaviours | At enrollment | The number of parasuicidal behaviours will be collected using Columbia Suicide Severity Rating Scale (C-SSRS). |
| Sick leave for a psychiatric condition | At enrollment | The number of sick leaves, related to BPD, and their duration will be collected and reported on the case report form (CRF). |
| Hospitalization for a psychiatric condition | At enrollment | The number of hospitalization, related to BPD, and their duration will be collected and reported on the case report form (CRF). |
| Number of SA compared to the biological data obtained in baseline | At enrollment | The number of SA will be collected using Columbia Suicide Severity Rating Scale (C-SSRS) and compared to the biological data obtained in baseline |
| Major depressive episodes | At enrollment | The number of major depressives episodes and the measure of the depression intensity will be collected using the Inventory of Depressive Symptomatology (IDS-C30). |
| Global functioning | At enrollment | The Global functioning will be measured using the Functioning Assessment Short Test (FAST). |
| Life Quality | At enrollment | The Life Quality will be measured using the Satisfaction With Life Scale (SWLS). |
| The need to emergency psychiatric consult | At enrollment | The number of emergency visit related to BPD, will be collected and reported on the case report form (CRF). |
| Suicidal Ideation | At enrollment | The number of suicidal ideation will be collected using Columbia Suicide Severity Rating Scale (C-SSRS). |
Countries
France
Contacts
Primary ContactDéborah DUCASSE, MD, PhD
Outcome results
None listed